X4 Pharmaceuticals, Inc. XFOR
3.01
0.01
0.33%
as of 25 Sep
- Market cap
- $297.4M
- P/E
- 0.0×
Follow XFOR
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | 0.00 | — | 0.00 | — | — |
P/S ratio |
4.82 | 26.56 | — | — | — | 0.00 | — | 0.00 | — | — |
P/FCF ratio |
10.54 | 0.00 | — | — | — | 0.00 | — | 0.00 | — | — |
P/Operating CF |
(10.90) | (4.47) | — | — | — | (7.37) | — | (0.95) | — | — |
P/B ratio |
0.91 | 6.66 | — | — | — | 1.77 | — | 0.00 | — | — |
Price to Tangible BV |
1.06 | 0.00 | — | — | — | 2.82 | — | 0.00 | — | — |
EV/Sales |
(0.19) | 21.90 | — | — | — | 0.00 | — | 0.00 | — | — |
EV/EBITDA |
0.08 | 0.00 | — | — | — | 0.00 | — | 0.00 | — | — |
EV/Operating CF |
0.08 | (0.93) | — | — | — | (1.43) | — | (0.32) | — | — |
EV/FCF |
(0.42) | (4.64) | — | — | — | (1.40) | — | (0.32) | — | — |
Quick Ratio |
9.84 | 3.16 | 5.02 | 5.50 | 5.89 | 6.66 | 13.57 | 1.39 | 7.34 | 0.36 |
Current Ratio |
10.16 | 3.41 | 5.34 | 5.76 | 6.27 | 6.97 | 13.68 | 1.18 | 7.45 | 0.47 |
Net Debt/EBITDA |
2.06 | 0.75 | 0.56 | 1.01 | 0.64 | 0.76 | 2.04 | (0.06) | 3.02 | (0.29) |
Debt/Assets |
26.27% | 51.50% | 37.06% | 21.61% | 28.96% | 27.00% | 13.06% | 98.87% | 12.21% | 133.18% |
Debt/Equity |
0.41 | 3.41 | 1.07 | 0.45 | 0.53 | 0.46 | 0.16 | (0.79) | 0.17 | (0.61) |
Asset Turnover |
0.16 | 0.02 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.08 | 0.00 | 0.00 |
Operating CF/Net income |
1.08 | 3.50 | 0.95 | 0.80 | 0.69 | 0.95 | 0.90 | 0.70 | 0.85 | 0.94 |
Capex/Depreciation |
(2.35) | 122.71 | (0.14) | (0.20) | (0.06) | (3.88) | 8.02 | (0.33) | (5.32) | (0.26) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (75.99%) | (102.26%) | (161.67%) | (139.26%) | (149.61%) | (61.51%) | (204.85%) | 395.09% | (2,330.44%) | 50.61% | |
| (36.25%) | (25.50%) | (66.81%) | (70.69%) | (85.52%) | (43.82%) | (62.59%) | (79.62%) | (56.26%) | (268.79%) | |
ROIC |
(566.65%) | 0.00% | 0.00% | 0.00% | (321.23%) | (137.23%) | (134.47%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(33.56%) | (46.77%) | (101.21%) | (89.72%) | (136.18%) | (85.58%) | (44.41%) | (2,170.17%) | (36.08%) | 394.85% |
Average Days of Receivables |
5.96 | 244.09 | 0.00 | 0.00 | 0.00 | 111.57 | 0.00 | 298.15 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
207.11% | 3,192.92% | 0.00% | 0.00% | 0.00% | 1,397.73% | 0.00% | 581.31% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
123.93% | 2,405.87% | 0.00% | 0.00% | 0.00% | 698.07% | 0.00% | 249.69% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.09 | 0.19 | 0.12 | 0.11 | 0.15 | 0.22 | 0.17 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
12.24% | 320.84% | 0.00% | 0.00% | 0.00% | 180.93% | 0.00% | 21.69% | 0.00% | 0.00% |
Graham Net Nets |
0.93 | (0.08) | — | — | — | 0.26 | — | (2.04) | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | 0.00 | — | 15,711.92 | — | — |
Earnings Yield |
(108.50%) | (25.91%) | — | — | — | (48.26%) | — | (521.47%) | — | — |
Free Cash Flow Yield |
9.49% | (17.77%) | — | — | — | (46.66%) | — | (398.75%) | — | — |
Revenue per Share |
0.83 | 0.38 | 0.00 | 0.00 | 0.00 | 4.49 | 0.00 | 228.76 | 0.00 | 0.00 |
Operating CF per Share |
(2.02) | (19.53) | (16.28) | (36.45) | (82.70) | (87.97) | (125.18) | (1,661.44) | (1,392.88) | (7,461.72) |
Capex per Share |
(0.07) | 14.57 | (0.01) | (0.05) | (0.72) | (2.04) | 2.15 | (2.22) | (24.71) | (25.17) |
Free Cash Flow per Share |
(2.10) | (4.96) | (16.29) | (36.50) | (83.41) | (90.01) | (123.02) | (1,663.66) | (1,417.58) | (7,486.90) |
Cash per Share |
5.98 | 15.23 | 19.27 | 57.54 | 95.39 | 117.72 | 328.69 | 531.63 | 5,019.15 | 1,046.55 |
Shareholders Equity per Share |
4.40 | 3.30 | 8.62 | 35.01 | 75.12 | 108.88 | 336.60 | (811.18) | 3,837.06 | (5,766.90) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.40 | 3.30 | 8.62 | 35.01 | 75.12 | 108.88 | 336.60 | (811.18) | 3,837.06 | (5,766.90) |
Free Cash Flow |
(88.62) | (33.23) | (96.57) | (77.20) | (71.52) | (60.18) | (47.23) | (25.45) | (21.69) | (21.71) |
Working Capital |
235.82 | 79.30 | 99.21 | 106.35 | 73.86 | 71.36 | 119.83 | 1.43 | 68.85 | (6.34) |
Capital Expenditures |
(3.00) | 97.67 | (0.06) | (0.10) | (0.61) | (1.36) | 0.83 | (0.03) | (0.38) | (0.07) |
Net Current Asset Value |
157.41 | (12.12) | 25.92 | 47.14 | 35.11 | 33.24 | 97.80 | (13.02) | 56.98 | (18.61) |
EV/EBIT |
0.08 | 0.00 | — | — | — | 0.00 | — | 0.00 | — | — |
Capex to Sales |
0.09 | (38.20) | 0.00 | 0.00 | 0.00 | 0.45 | 0.00 | 0.01 | 0.00 | 0.00 |
Net Profit Margin |
(225.55%) | (1,464.61%) | 0.00% | 0.00% | 0.00% | (2,071.03%) | 0.00% | (1,037.34%) | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | — | — | — | 0.00 | — | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
7.02 | 1.03 | 0.56 | 0.46 | 6.77 | 0.28 | 0.26 | 0.43 | 0.17 | 0.55 |
Cash ROIC |
(16.64%) | (65.96%) | (44.23%) | (34.09%) | (40.20%) | (32.52%) | (17.53%) | (461.94%) | (14.94%) | 622.07% |
Accounts Receivable Turnover |
30.76 | 2.25 | 0.00 | 0.00 | 0.00 | 2.06 | 0.00 | 1.57 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.80 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
1.58 | 0.00 | — | — | — | — | — | — | — | — |
Average Days of Payables |
361.13 | 3,948.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
283.97 | 1,290.09 | — | — | — | — | — | — | — | — |
Average Receivables |
1.14 | 1.14 | 0.86 | 0.95 | 0.83 | 1.46 | 2.43 | 2.23 | 1.48 | 1.44 |
Average Payables |
7.16 | 8.78 | 8.36 | 6.03 | 3.71 | 2.62 | 2.53 | 2.43 | 1.77 | 1.03 |
Average Inventory |
3.65 | — | — | — | — | — | — | — | — | — |
Average Assets |
218.45 | 146.85 | 151.42 | 136.38 | 120.02 | 141.78 | 85.32 | 45.60 | 44.43 | 8.56 |
Average Common Equity |
104.22 | 36.62 | 62.58 | 69.23 | 68.61 | 101.01 | 26.07 | (9.19) | 1.07 | (45.44) |
Columns are period end dates